{"filings":[{"id":3468757,"accession_number":"0001493152-26-047168","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2026-10-15T13:30:14+00:00","items":["8.01","9.01"],"status":"ready","headline":"bioAffinity to sponsor CHEST 2026 Learning Theater on CyPath Lung and asthma/COPD research","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["bioAffinity Technologies (Nasdaq: BIAF, BIAFW) will sponsor a Learning Theater at CHEST 2026 on Oct. 21, 2026, 12:30-1:15 p.m. MST in Phoenix.","Chief Medical Officer Gordon H. Downie, MD, PhD, will present on CyPath Lung for lung cancer risk stratification and pulmonary nodule management.","CyPath Lung clinical trial data: 92% sensitivity, 87% specificity, 88% accuracy, 99% negative predictive value for small indeterminate nodules under 20 mm.","Presentation will discuss preliminary data from an investigational asthma/COPD lung inflammation test.","Medical and Scientific Advisory Board to meet; members include David Hill, David Ost, Daniel Sterman, Sheila Habib, J. Scott Ferguson, Neil Alexis and Sandeep Bansal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":3413916,"accession_number":"0001493152-26-046755","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2026-10-13T13:23:00+00:00","items":["8.01","9.01"],"status":"ready","headline":"bioAffinity to present CHEST 2026 data on sputum tests for asthma and COPD lung inflammation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["bioAffinity will present poster 3071 at CHEST 2026 on Oct. 20 in Phoenix on sputum-based tests measuring lung inflammation in asthma and COPD.","Research measured targets TSLP, CRLF2, IL4-Rα (CD124) and IL-5, linked to drugs tezepelumab, verkitug, dupilumab and mepolizumab.","Sputum samples came from people with asthma, smokers with/without COPD, a smoker with both COPD and asthma, and healthy individuals; flow cytometry, ELISA and machine learning were used.","CyPath Lung, marketed as an LDT, showed 92% sensitivity, 87% specificity, 88% accuracy and 99% NPV for lung cancer in high-risk patients with nodules under 20 mm.","Global asthma therapeutics market was about $29.7 billion in 2025 and is projected to reach $47.6 billion by 2034."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":3374397,"accession_number":"0001493152-26-046548","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2026-10-09T20:30:27+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"bioAffinity Technologies closes $4M registered direct offering and concurrent private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered Oct 8, 2026 securities purchase agreement for 116,545 shares at $6.122 and pre-funded warrants for 536,836 shares at $6.115.","Concurrent private placement issued warrants for up to 980,072 shares at $6.122, exercisable after stockholder approval and expiring five years later.","Gross proceeds approximately $4 million; closing occurred Oct 9, 2026; net proceeds for working capital and CyPath Lung sales support.","WallachBeth Capital LLC is sole placement agent; cash fee 7.5% of gross proceeds, $70,000 expenses, and warrants for 19,602 shares at $6.122.","Company suspended ATM prospectus supplement dated May 27, 2025 under sales agreement with Placement Agent; sales agreement remains in effect."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":3328836,"accession_number":"0001493152-26-046266","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2026-10-08T12:30:37+00:00","items":["8.01","9.01"],"status":"ready","headline":"bioAffinity Technologies Receives Japan Patent Allowance for CyPath Lung Early Lung Cancer Test","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Japan Patent Office issued a Notice of Allowance for bioAffinity's method of predicting lung cancer likelihood using the CyPath Lung test and AI-built algorithm.","Patent would be the first awarded in Japan for CyPath Lung and the fifth protecting the early lung cancer test in Asia, including China and Hong Kong.","bioAffinity's portfolio includes 22 awarded U.S. and foreign patents and 36 pending applications; issuance expected after payment of applicable fee.","CEO Maria Zannes said the patent strengthens IP protection in Asian markets; CyPath Lung showed 92% sensitivity, 87% specificity, 88% accuracy, and 99% NPV.","Company trades on Nasdaq Capital Market under BIAF for common stock and BIAFW for warrants to purchase common stock."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":3274281,"accession_number":"0001493152-26-045867","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2026-10-06T12:30:20+00:00","items":["8.01","9.01"],"status":"ready","headline":"bioAffinity reports CyPath Lung sales up over 100% through Q3 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CyPath Lung sales rose more than 100% through Q3 2026 versus 2025, with 1,620 tests delivered compared to 775 in Q3 2025.","Ordering physicians increased 89% in Q3 2026 versus Q3 2025; prior prescribers' sales volume rose 48% year-over-year.","CEO Maria Zannes cited a new distribution agreement with Veteran-Owned AvMEDICAL to broaden reach in government healthcare, including the Department of Veterans Affairs.","CyPath Lung reported 92% sensitivity, 87% specificity, 88% accuracy and 99% negative predictive value in high-risk patients with nodules under 20 mm."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":3163199,"accession_number":"0001493152-26-045034","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2026-09-30T12:30:29+00:00","items":["8.01","9.01"],"status":"ready","headline":"bioAffinity debuts CyPath Lung with AvMEDICAL at NAVREF conference to 300+ VA physicians","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["bioAffinity and AvMEDICAL, a Service-Disabled Veteran-Owned Small Business, held the first joint CyPath Lung exhibition at NAVREF 2026 in Arlington, Virginia, reaching 300+ attendees.","The VA reports about 7,700 veterans are diagnosed with lung cancer each year; the federal distribution agreement aims to expand veteran access to the noninvasive test.","CyPath Lung showed 92% sensitivity, 87% specificity, 88% accuracy and 99% negative predictive value in a published trial of high-risk patients with nodules under 20 mm.","bioAffinity also presented CyPath Lung at the GO2 for Lung Cancer Centers of Excellence conference in San Diego; GO2 works with the VA and 700+ screening centers.","The nationwide agreement uses AvMEDICAL's government contracting expertise and procurement channels; AvMEDICAL has more than doubled its product portfolio since 2020."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":3000636,"accession_number":"0001493152-26-043654","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2026-09-22T12:30:39+00:00","items":["8.01","9.01"],"status":"ready","headline":"bioAffinity presents CyPath Lung data at NAVREF 2026; cites 92% sensitivity in veteran study","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Two posters presented Sept 27-30, 2026 in Arlington, VA: one on 3 clinical cases, one on FlowPath Lung study.","FlowPath Lung: 2,000-patient longitudinal study in veterans/military, enrolling at 12 VA centers and 2 military hospitals.","CyPath Lung reported 92% sensitivity, 87% specificity, 99% NPV for pulmonary nodules ≤20 mm.","Poster cites 2024 economic analysis projecting hundreds of millions in potential VA screening savings.","Company appears with new distribution partner AvMEDICAL at first joint federal healthcare market engagement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2917439,"accession_number":"0001493152-26-043052","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2026-09-17T12:30:40+00:00","items":["8.01","9.01"],"status":"ready","headline":"bioAffinity Technologies wins Hong Kong patent for CyPath Lung lung cancer diagnostic","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Hong Kong IP Department granted Patent No. HK40048460 covering flow cytometry and fluorescent markers in sputum for lung cancer prediction.","Patent complements 2025 China patent; strengthens IP in Asia, which accounts for ~1.6M new lung cancer cases annually.","CyPath Lung clinical trial data: 92% sensitivity, 87% specificity, 88% accuracy, 99% NPV in high-risk patients with nodules <20mm.","Company holds patents/pending in US, Australia, Canada, China, EU, Japan, Mexico, Singapore."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2806316,"accession_number":"0001493152-26-042304","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2026-09-11T12:30:44+00:00","items":["7.01","9.01"],"status":"ready","headline":"bioAffinity furnishes presentation slides for H.C. Wainwright conference; no figures in 8-K body","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation materials (Exhibit 99.1) cover operations and performance; specifics only in the exhibit.","Materials to be used at H.C. Wainwright 28th Annual Global Investment Conference, Sept 14-16, 2026.","Report signed by President/CEO Maria Zannes; no financial or operational data disclosed in body.","Common stock (BIAF) and warrants (BIAFW) trade on Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2751878,"accession_number":"0001493152-26-041894","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2026-09-09T12:30:16+00:00","items":["8.01","9.01"],"status":"ready","headline":"bioAffinity regains Nasdaq compliance; hearing cancelled, listing continues","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Regained compliance with Nasdaq Minimum Bid Price Rule 5550(a)(2) and Rights/Warrants Rule 5560(a) as of Sept 8, 2026.","Previously scheduled Nasdaq Hearings Panel hearing cancelled; BIAF and BIAFW continue trading on Nasdaq Capital Market.","As of Sept 8, 2026: 1,166,625 shares outstanding; aggregate market value ~$10.4M based on closing price.","Staff Determination on July 30, 2026 cited bid price below $1.00 for 30 consecutive days; appeal filed Aug 6, 2026.","CEO Maria Zannes: pleased to regain compliance, focus on CyPath Lung test and pipeline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2660596,"accession_number":"0001493152-26-041387","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2026-09-03T20:55:07+00:00","items":["8.01","9.01"],"status":"ready","headline":"bioAffinity CEO to present at H.C. Wainwright conference Sept 14-16, 2026","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["President/CEO Maria Zannes will present corporate update and hold one-on-one investor meetings at H.C. Wainwright 28th Annual Global Investment Conference, Sept 14-16, 2026.","Presentation to feature CyPath Lung diagnostic test commercial adoption and technology platform advancements for diagnostics and therapeutics.","As of Sept 2, 2026, company had 600,736 common shares outstanding; aggregate market value ~$5.9M based on Nasdaq closing price.","Live and archived webcast of presentation available Sept 11 at https://bit.ly/BIAFPresentation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2604961,"accession_number":"0001493152-26-041020","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2026-09-01T20:30:23+00:00","items":["8.01","9.01"],"status":"ready","headline":"bioAffinity advances CyPath Lung for surveillance of lung cancer survivors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Announces potential use of CyPath Lung for post-treatment surveillance; >680,000 Americans living with prior lung cancer diagnosis.","NSCLC recurrence after curative treatment runs 20-55%; ASCO recommends imaging every 6 months for 2 years.","CyPath Lung detection trial: 92% sensitivity, 87% specificity, 88% accuracy, 99% NPV; not yet validated for surveillance.","Company cites 3 years of commercial experience and case studies supporting risk stratification of challenging nodules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2365000,"accession_number":"0001493152-26-039375","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2026-08-20T12:30:43+00:00","items":["3.03","5.03","7.01","9.01"],"status":"ready","headline":"bioAffinity Technologies announces 1-for-15 reverse stock split to regain Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split effective at open of trading on Aug 24, 2026; every 15 shares become 1 share of BIAF.","Post-split shares outstanding ~592,373; new CUSIP 09076W406.","Split aims to meet Nasdaq minimum bid price requirement; no change to authorized shares or par value.","Proportionate adjustments made to outstanding stock options, RSUs, and warrants; fractional shareholders get cash.","Stockholders of record receive transfer agent notice; trading symbol remains BIAF."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2310437,"accession_number":"0001493152-26-038897","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2026-08-18T12:30:29+00:00","items":["8.01","9.01"],"status":"ready","headline":"bioAffinity signs distribution agreement with AvMEDICAL for CyPath Lung in federal healthcare","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Distribution agreement with AvMEDICAL (SDVOSB) to market CyPath Lung to federal agencies, including VA medical centers.","AvMEDICAL's sales force and IDIQ contract access expected to expand government procurement of CyPath Lung.","CyPath Lung clinical data: 92% sensitivity, 87% specificity, 88% accuracy, 99% NPV in high-risk patients with nodules <20mm.","VA context: ~8,000 veterans diagnosed with lung cancer annually; ~5,000 die; early detection goal.","Co-branded marketing and AvMEDICAL promotion to federal customers; no financial terms disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2272357,"accession_number":"0001493152-26-038437","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2026-08-14T20:30:19+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"bioAffinity raises $4M via private placement of 8.46M shares and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$4.0M; net proceeds ~$3.6M after fees; closed Aug 14, 2026.","Sold 8,462,027 shares (or pre-funded warrants) at $0.4727 combined with two warrants; pre-funded at $0.4657.","Warrants exercisable at $0.4727, expire in 5 years, subject to stockholder approval; pre-funded at $0.007.","Placement agent WallachBeth Capital gets 7.5% cash fee and warrants for 253,861 shares.","Proceeds for working capital and general corporate purposes; resale registration due within 15 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2115762,"accession_number":"0001493152-26-036486","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2026-08-07T12:30:17+00:00","items":["2.02","9.01"],"status":"ready","headline":"bioAffinity Q2 revenue up 19% to $1.5M; CyPath Lung volume +216% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2026 revenue $1.5M, up 19% YoY; net loss narrowed to $3.4M from $4.1M.","CyPath Lung test volume +216% YoY; H1 revenue from test +159% to ~$835k; 1,097 reports vs 390.","Cash and equivalents $2.4M at June 30, 2026 vs $6.4M at Dec 31, 2025; completed $3.2M public offering in June.","Pipeline: asthma/COPD diagnostics and skin cancer therapeutics; longitudinal trial at 11 sites incl. VA.","Physician offices ordering test up 122%; existing clients' orders +71% H1 YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1997477,"accession_number":"0001493152-26-035672","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2026-07-31T21:15:15+00:00","items":["3.01"],"status":"ready","headline":"bioAffinity receives Nasdaq delisting notice for bid price non-compliance; plans appeal","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Staff Determination on July 30, 2026, for bid price below $1.00 for 30 consecutive business days.","Not eligible for 180-day compliance period due to reverse stock split within prior year (1-for-30 on Sept 19, 2025).","Intends to appeal on August 6, 2026, which will stay delisting pending panel decision.","No assurance of regaining compliance or continued listing on Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1868680,"accession_number":"0001493152-26-034711","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2026-07-27T12:30:31+00:00","items":["8.01","9.01"],"status":"ready","headline":"bioAffinity Technologies publishes clinical framework for CyPath Lung in nodule evaluation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["White paper by CMO Gordon Downie proposes specialty-specific pathways for pulmonology, primary care, oncology using CyPath Lung.","CyPath Lung demonstrated 92% sensitivity, 87% specificity, 88% accuracy, 99% NPV in high-risk patients with small nodules.","Company reports 7.78M shares outstanding, market cap ~$5.1M as of July 24, 2026.","CyPath Lung analyzes sputum for lung microenvironment, not blood-based, providing real-time information.","Complete white paper available at https://bit.ly/cypath-lung-whitepaper3."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1785279,"accession_number":"0001493152-26-034183","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2026-07-22T12:30:27+00:00","items":["8.01","9.01"],"status":"ready","headline":"bioAffinity Technologies partners with Pictor to develop asthma/COPD diagnostics","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Collaboration integrates bioAffinity's flow cytometry with Pictor's targeted proteomic platform for lung inflammation tests.","Tests aim to match asthma/COPD patients with personalized treatments; asthma/COPD affect 40M Americans and 650M worldwide.","Global asthma/COPD therapeutics market projected to exceed $108B in 2026 and $155B by 2030.","bioAffinity will own IP for tests developed; Pictor retains its platform IP and owns new platform inventions.","Tests initially offered as Laboratory Developed Tests under CLIA; no financial terms disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1481636,"accession_number":"0001493152-26-032263","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2026-07-07T12:54:20+00:00","items":["8.01","9.01"],"status":"ready","headline":"bioAffinity Technologies reports Q2 2026 CyPath Lung sales up >200% YoY, record quarter","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q2 2026 CyPath Lung sales volume >200% YoY and >30% over Q1 2026.","Nearly 3,000 tests performed since commercial launch.","155% increase in physician offices ordering CyPath Lung vs Q2 2025.","Company expects to report Q2 2026 financial results in August.","Initiatives include longitudinal study, oncology expansion, asthma/COPD tests."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1362917,"accession_number":"0001493152-26-031327","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2026-06-30T21:19:20+00:00","items":["8.01","9.01"],"status":"ready","headline":"bioAffinity reports 300% YoY CyPath Lung sales growth in April; partners with Philips for veteran screening","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CyPath Lung unit sales in April 2026 increased nearly 300% vs. April 2025; ordering physician sites up 69% Q1 2025 to Q1 2026.","Collaboration with Philips to enhance lung cancer screening for U.S. veterans using mobile CT, CyPath Lung, and 4DMedical software.","Pilot study with Brooke Army Medical Center underway for asthma/COPD companion diagnostics using flow cytometry+AI.","Preclinical research shows siRNA silencing selectively kills squamous skin cancer cells, suggesting topical treatment for basal/squamous cell carcinomas.","Recent news includes Mexico patent allowance for CyPath Lung technology and record monthly sales in April 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1140596,"accession_number":"0001493152-26-029384","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2026-06-18T21:07:11+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"bioAffinity Technologies closes $3.2M public offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 1,040,000 shares at $0.80 each and pre-funded warrants for 2,960,000 shares at $0.793 each.","Gross proceeds of $3.2M before fees; net proceeds for working capital and general corporate purposes.","Post-closing common shares outstanding: 6,283,061.","Placement agent WallachBeth Capital LLC received 7.5% fee plus $120,000 expense reimbursement.","Company subject to 30-day lock-up on equity issuances and 3-month ban on variable-rate transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1066478,"accession_number":"0001493152-26-028823","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2026-06-16T12:30:22+00:00","items":["8.01","9.01"],"status":"ready","headline":"bioAffinity Technologies to host veteran lung cancer webinar July 21, 2026","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Webinar features Philips, 4DMedical, and NAVREF discussing lung health screening for veterans.","CyPath Lung test cited: 92% sensitivity, 87% specificity, 99% NPV in published trial.","Event is educational; no financial guidance or operational updates provided.","No changes to company outlook or product commercialization disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":788160,"accession_number":"0001493152-26-026773","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2026-06-02T12:30:28+00:00","items":["8.01","9.01"],"status":"ready","headline":"bioAffinity SAB webinar on CyPath Lung for early lung cancer detection on June 16","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Society for Advanced Bronchoscopy hosts free webinar June 16, 7pm ET on CyPath Lung's role in early lung cancer detection.","Panel includes med onc Vijay Gunuganti, thoracic surgeon Reginald Baptiste, interventional pulmonologist Sai Guda.","CyPath Lung is a noninvasive sputum test using flow cytometry and AI; published trial: 92% sensitivity, 87% specificity, 99% NPV for nodules <20mm.","Webinar to discuss real-world benefits: guiding surgery, reducing unnecessary procedures, supporting surveillance.","CEO Maria Zannes notes collaboration with SAB to advance minimally invasive lung diagnostics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":677999,"accession_number":"0001493152-26-025338","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2026-05-27T12:30:16+00:00","items":["8.01","9.01"],"status":"ready","headline":"bioAffinity Technologies announces Mexican patent allowance for CyPath Lung cancer detection method","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mexican patent allowance for flow-cytometry methods to detect lung cancer using CyPath Lung.","Patent will protect use of defined antibodies and TCPP porphyrin to label sputum cells.","CyPath Lung demonstrated 92% sensitivity, 87% specificity, 88% accuracy, 99% NPV in trial.","IP portfolio now includes patents in US, EU, China, Japan, Australia, Canada, and Mexico."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":24001,"accession_number":"0001493152-26-022428","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2026-05-12T13:20:15+00:00","items":["8.01","9.01"],"status":"ready","headline":"bioAffinity CyPath Lung unit sales nearly 300% higher in April 2026 vs 2025","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Record monthly CyPath Lung unit sales in April 2026; preliminary data shows ~300% YoY increase over April 2025.","Sales growth so far in 2026 exceeds internal projections, reflecting accelerating physician adoption.","CyPath Lung uses flow cytometry + AI for noninvasive lung cancer detection; 92% sensitivity, 87% specificity in trial.","Company advancing longitudinal clinical study, expanding use for lung cancer survivor monitoring, and R&D pipeline for asthma/COPD.","CEO Maria Zannes highlights CyPath Lung's role in risk stratification and nodule management."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94923,"accession_number":"0001493152-26-021861","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2026-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"bioAffinity Q1 2026: CyPath Lung sales +146% YoY, revenue $1.4M, net loss $3.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["CyPath Lung unit sales rose 146% YoY; testing revenue up 114% to $361,000.","Total revenue $1.4M, down 27% from $1.9M due to discontinuing unprofitable pathology services.","Net loss $3.6M ($0.81/share) vs $2.7M ($4.80/share) in Q1 2025; cash $3.1M.","Physician offices ordering CyPath Lung increased 69% YoY; company expects acceleration.","Launched DoD-funded longitudinal trial; Brooke Army Medical Center study for asthma/COPD companion tests."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.81,"consensus_revenue_estimate":null,"consensus_revenue_actual":1351527.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94922,"accession_number":"0001493152-26-020591","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"BioAffinity stockholders approve reverse stock split, 2024 plan share increase to 1M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved reverse stock split at ratio of 1-for-2 to 1-for-250, at board's discretion.","Plan amended to increase shares reserved under 2024 Plan from 66,666 to 1,000,000.","Approved warrant exercise of up to 271,500 shares and anti-dilution adjustments (floor $4.50 for warrants, $3.00 for Series B).","Six directors elected: Maria Zannes, Steven Girgenti, Peter Knight, Jamie Platt, Roberto Rios, John J. Oppenheimer.","Ratified WithumSmith+Brown as independent auditor for fiscal year 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94921,"accession_number":"0001493152-26-016486","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2026-04-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CyPath® Lung case study shows test helped defer biopsy for high-risk patient with 30mm nodule","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["70-year-old female, 50 pack-year smoking history, 30mm lung nodule with high cancer risk by imaging and models.","CyPath® Lung returned negative result ('Unlikely Malignancy'); follow-up CT showed nodule had completely resolved.","Treating pulmonologist credited CyPath® Lung for prompting additional imaging before scheduled biopsy.","CyPath® Lung demonstrated 92% sensitivity, 87% specificity, and 88% accuracy in detecting lung cancer in small nodules in clinical trial.","Case illustrates potential to avoid risky, unnecessary procedures in patients with comorbidities like emphysema."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94920,"accession_number":"0001493152-26-015445","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2026-04-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"bioAffinity Technologies' CyPath Lung featured at Cleveland Clinic symposium Apr 16","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CyPath Lung test to be highlighted at invitation-only 'Advances in Early Lung Cancer Detection' symposium.","CMO Gordon Downie, MD, PhD, to serve on panel discussing lung nodule management.","Test has demonstrated 92% sensitivity, 87% specificity, and 88% accuracy in detecting early-stage lung cancer.","This marks the company's seventh invitation to present at the Cleveland Clinic symposium."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94919,"accession_number":"0001493152-26-014653","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2026-04-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"bioAffinity Q1 2026 CyPath Lung unit sales surge 146% YoY, beat projections","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q1 2026 CyPath Lung unit sales up 146% YoY, exceeding internal projections on accelerating physician adoption.","Full-year 2025 CyPath Lung revenue rose 87% YoY, units sold up 99% vs 2024.","Addressable U.S. market estimated at $3.58 billion; capturing 10% would represent $358M in sales.","Company advancing large-scale clinical study and R&D pipeline for asthma/COPD diagnostics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107640,"accession_number":"0001493152-26-012808","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2026-03-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"bioAffinity posts investor presentation on website; no financial details in filing","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Presentation materials made available on company website on March 26, 2026.","The 8-K filing does not include specific operational or financial updates.","Tickers referenced: BIAF (common) and BIAFW (warrants).","No quantitative guidance or material events disclosed in the furnished exhibit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107639,"accession_number":"0001493152-26-012683","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2026-03-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"bioAffinity Technologies announces virtual physician roundtable on CyPath® Lung for April 8, 2026","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Webinar titled 'CyPath® Lung in Practice: A Physician Roundtable Discussion' on April 8, 2026 at 7 p.m. ET.","Moderated by CMO Gordon H. Downie, MD, PhD; panel includes three pulmonologists sharing real-world cases.","CyPath® Lung achieved 92% sensitivity, 87% specificity, 88% accuracy in detecting lung cancer in high-risk patients with small nodules.","First of a series aimed at integrating noninvasive CyPath® Lung into pulmonary practice for nodule management."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107638,"accession_number":"0001493152-26-010584","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2026-03-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"bioAffinity case study shows CyPath Lung avoided invasive biopsy in high-risk nodule patient","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["71-year-old former smoker with multiple lung nodules received CyPath Lung 'Unlikely Malignancy' result.","Physician delayed invasive biopsy based on test result; follow-up CT showed nodules resolved or stable.","CyPath Lung demonstrated 92% sensitivity, 87% specificity, 88% accuracy in clinical study for nodules <20mm.","Case study underscores noninvasive test's potential to reduce patient anxiety and lower healthcare costs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107637,"accession_number":"0001493152-26-009986","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2026-03-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"bioAffinity 2025 revenue $6.2M; CyPath Lung revenue up 87% YoY, net loss $14.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $6.2M, down 34% from $9.4M in 2024 due to discontinuing unprofitable pathology services.","CyPath Lung revenue increased 87% YoY; tests performed up 99%, physician orders up 67%.","Net loss $14.9M vs $9.0M in 2024, driven by warrant fair value changes and higher commercialization costs.","Cash $6.5M at year-end; raised $16.9M in equity in 2025. Guidance: >100% CyPath Lung unit sales growth in 2026.","Appointed Gordon Downie MD PhD as CMO; Roberto Rios CPA and John Oppenheimer MD to board of directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107636,"accession_number":"0001493152-26-009463","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2026-03-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"bioAffinity initiates 2K-patient longitudinal study for CyPath Lung diagnostic","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["2,000-patient longitudinal study to evaluate CyPath Lung for early lung cancer detection in high-risk patients with nodules 6-29mm.","Study will include up to 20 sites, including a dozen VA medical centers and two large military hospitals.","Earlier trial showed 92% sensitivity, 87% specificity, 88% accuracy in detecting lung cancer in nodules <20mm.","Enrollment expected up to 18 months; patients followed up to 24 months or until definitive diagnosis.","Murtha Cancer Center Research Program provides support and funding for federal facilities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107635,"accession_number":"0001493152-26-009154","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2026-03-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Two directors not standing for re-election at bioAffinity Technologies' 2026 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Robert Anderson and Roby Joyce informed the board on March 5, 2026 of their decisions not to stand for re-election.","Their terms expire at the Annual Meeting currently scheduled for April 30, 2026.","The decisions did not result from any disagreements with the company on operations, policies, or practices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107634,"accession_number":"0001493152-26-008723","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2026-03-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"bioAffinity presents positive data on sputum diagnostics to match asthma/COPD patients with therapies","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Poster presented at AAAAI 2026 annual meeting on March 1, 2026, reports ability to identify antibody drug receptors in sputum.","Technology detected receptors for dupilumab and benralizumab, leading asthma/COPD therapies.","Company leveraging CyPath® Lung flow cytometry and AI platform for new asthma/COPD diagnostic tests.","CyPath® Lung commercial test has 92% sensitivity, 87% specificity for early-stage lung cancer detection."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107633,"accession_number":"0001493152-26-007965","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"bioAffinity Technologies announces validation study with Brooke Army Medical Center for CyPath Lung test","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Study with BAMC to validate CyPath Lung on sputum obtained by tracheal/bronchial suctioning for early lung cancer detection.","Enrolling 30-50 patients; results expected by mid-2026.","Potential to expand sample collection options; currently patients collect sputum at home.","U.S. bronchoscopy procedures ~500,000 annually; market valued at $700-920M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107632,"accession_number":"0001493152-26-007464","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2026-02-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"bioAffinity Technologies releases case study showing CyPath Lung helps avoid biopsy in elderly patient","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CyPath Lung test was negative for a 79-year-old woman with suspicious LDCT finding, supporting surveillance over invasive biopsy.","Repeat CT scan in October 2025 showed nodule resolved, validating the conservative management decision.","Test demonstrated 92% sensitivity, 87% specificity, and 88% accuracy for detecting lung cancer in nodules <2 cm.","Case study highlights CyPath Lung's role in reducing unnecessary procedures in high-risk patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107631,"accession_number":"0001493152-26-007139","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2026-02-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"bioAffinity Technologies publishes CyPath Lung case study showing 92% sensitivity in small nodules","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CyPath Lung test demonstrated 92% sensitivity, 87% specificity, and 88% accuracy for detecting lung cancer in nodules <2 cm.","Case study: 59-year-old with 30-year smoking history, COPD, multiple Lung-RADS 3 nodules; negative CyPath result.","Negative result allowed continued CT surveillance; follow-up CT showed stable nodules, avoiding invasive procedures.","Company markets test as LDT; case study reinforces clinical utility for reducing anxiety and supporting treatment decisions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107630,"accession_number":"0001493152-26-006004","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2026-02-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"bioAffinity posts new presentation materials; no details in filing","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company published new investor presentation on its website as of February 10, 2026.","Presentation materials intended for use in management discussions about operations and performance.","No specific financial or operational updates from the presentation are included in this 8-K filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107629,"accession_number":"0001493152-26-005796","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2026-02-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"bioAffinity appoints three lung cancer specialists to Medical and Scientific Advisory Board","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["David Ost (MD Anderson), Daniel Sterman (NYU Langone) and J. Scott Ferguson (Univ. of Wisconsin) joined the advisory board.","Advisory board provides guidance on clinical priorities and broader adoption of CyPath® Lung diagnostic test.","CyPath® Lung is a noninvasive test for early lung cancer detection with 92% sensitivity and 87% specificity in clinical studies.","New appointees join current members including David Hill, Neil Alexis, Sheila Habib, and Sandeep Bansal.","Company says appointments align with its focus on integrating CyPath® Lung into standard care for indeterminate pulmonary nodules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107628,"accession_number":"0001493152-26-005109","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2026-02-04T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"bioAffinity Technologies sets 2026 Annual Meeting for April 30; proposal deadline Feb 14","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Annual Meeting scheduled for April 30, 2026 at company's principal executive offices in San Antonio, TX.","Special Meeting of Stockholders (Dec 19, 2025) adjourned without business due to lack of quorum; proposals will be included in Annual Meeting.","Stockholder proposals or director nominations must be received by Feb 14, 2026, ten days after this announcement.","Details of proposals and proxy statement to be filed with SEC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107627,"accession_number":"0001493152-26-000814","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2026-01-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"bioAffinity Technologies maintains CAP accreditation for lab subsidiary PPLS","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Precision Pathology Laboratory Services (PPLS) passed rigorous CAP on-site inspection, retaining gold-standard accreditation.","Reaffirms quality, accuracy, and patient safety for CyPath Lung test and all lab services lines.","CEO states ongoing CAP accreditation supports value proposition with physicians, health systems, and partners.","Lung cancer diagnostics market projected to grow from $4.8B (2024) to $10.4B by 2034 at 8.1% CAGR.","CyPath Lung test demonstrates 92% sensitivity, 87% specificity, 88% accuracy in detecting early-stage lung cancer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124009,"accession_number":"0001493152-25-028809","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2025-12-22T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Dr. Joyce transfers Village Oaks Pathology equity to Dr. Humphreys; new succession agreement executed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dr. Joyce (77) informed Company of desire to transfer 100% stock of Village Oaks Pathology to Dr. Humphreys; not due to disagreement.","On Dec 22, 2025, Village Oaks Pathology, PPLS, and Dr. Humphreys entered a Succession Agreement restricting disposal of equity.","Agreement provides for automatic transfer of equity to a successor upon death, disability, retirement, incompetence, or failure to meet eligibility requirements.","Dr. Humphreys must use commercially reasonable efforts to preserve Village Oaks Pathology's operations, contracts, and licenses."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124008,"accession_number":"0001493152-25-028584","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2025-12-19T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"bioAffinity adjourns special meeting due to lack of quorum; reconvenes Jan 19, 2026","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Special meeting of stockholders adjourned Dec 19, 2025 because insufficient shares present for quorum.","Adjourned meeting will reconvene Jan 19, 2026 at 8:00 a.m. Central Time.","Record date remains Nov 4, 2025; proposals voted on unchanged.","Stockholders who already voted need not take action; proxies remain valid."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124007,"accession_number":"0001493152-25-025893","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2025-12-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"bioAffinity to present CyPath Lung data showing Stage 1A detection in challenging cases at ACS NLCRT Dec 8","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CyPath Lung identified Stage 1A lung cancer in three patients with atypical presentations.","Poster session at American Cancer Society National Lung Cancer Roundtable on Dec 8, 2025, 2:35-3:15 p.m. ET.","Chief Medical Officer Gordon Downie presenting cases from Titus Regional Hospital Lung Nodule Clinic.","Test uses flow cytometry and AI on sputum; prior study showed 92% sensitivity and 87% specificity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124006,"accession_number":"0001493152-25-022604","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"bioAffinity Q3 2025: revenue down to $1.5M, CyPath Lung revenue up 122% YoY, net loss $5.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $1.5M in Q3 2025, down 38% from $2.4M in Q3 2024 due to discontinuation of unprofitable pathology services.","CyPath Lung testing revenue increased 122% YoY; test volumes up 97% in first nine months of 2025.","Net loss $5.1M ($4.74 per share) compared to $2.0M loss ($4.84 per share) in Q3 2024, driven by change in fair value of warrants.","Raised $10.4M gross proceeds from equity transactions; cash and equivalents increased to $7.7M from $1.1M at year-end 2024.","Appointed Roberto Rios and John J. Oppenheimer to board; regained full Nasdaq compliance for listing of BIAF and BIAFW."],"consensus_eps_estimate":null,"consensus_eps_actual":-7.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":4569146.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124005,"accession_number":"0001493152-25-020816","cik":1712762,"company_name":"bioAffinity Technologies, Inc.","ticker":"BIAF","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"bioAffinity reports CyPath Lung test volume up 111% in Oct vs 2025 monthly avg","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["October test volume increased 111% over 2025 monthly average; Q3 volume rose 95% sequentially.","Medical practices with multiple CyPath orders rose 106% QoQ in Q3 and 67% in Oct vs YTD monthly avg.","CyPath Lung noninvasive sputum test uses AI/flow cytometry; clinical study showed 92% sensitivity, 87% specificity.","CEO Maria Zannes cites growing physician trust and successful outreach to pulmonologists, health systems, VA centers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7482594.999999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2025-11-05T23:59:59+00:00|124005"}